Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens when ...

SEATTLE — March 5, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. March is the awareness month for colorectal cancer and multiple ...

Equillium, Inc. (NASDAQ:EQ) released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host ...

Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...

MiNK Therapeutics receives an NIAID grant to develop iNKT cell therapies for preventing graft-versus-host disease in stem cell transplants. MiNK Therapeutics, Inc., a biopharmaceutical company ...

Hematopoietic cell transplantation (HCT), also known as bone marrow transplantation, is a critical treatment for blood cancers such as leukemia, lymphoma, and myeloma, as well as certain genetic and ...

Refined response (RR) criteria for acute graft-vs-host disease (GVHD) showed improved predictive performance over conventional criteria, with higher area under the curve (AUC) values and negative ...

The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after ...